Expanding Therapeutic Utility of Carfilzomib for Breast Cancer Therapy by Novel Albumin-coated Nanocrystal Formulation

Carfilzomib (CFZ) is the second-in-class proteasome inhibitor with much improved efficacy and safety profiles over bortezomib in multiple myeloma patients. In expanding the utility of CFZ to solid cancer therapy, the poor aqueous solubility and in vivo instability of CFZ are considered major drawbac...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:J Control Release
Autori principali: Park, Ji Eun, Park, Joonyoung, Jun, Yearin, Oh, Yunseok, Ryoo, Gongmi, Jeong, Yoo-Seong, Gadalla, Hytham H., Min, Jee Sun, Jo, Jung Hwan, Song, Myung Geun, Kang, Keon Wook, Bae, Soo Kyung, Yeo, Yoon, Lee, Wooin
Natura: Artigo
Lingua:Inglês
Pubblicazione: 2019
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC6638563/
https://ncbi.nlm.nih.gov/pubmed/30954620
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jconrel.2019.04.006
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi